SCHEMBL1764576

SCHEMBL1764576

CC(C)COC(=O)ON1C(=O)CCC1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.49
MEN1 O00255 2/20 0.49
LMNA P02545 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2C9 P11712 1/20 0.49
NFKB1 P19838 1/20 0.49
PTGS1 P23219 1/20 0.49
APEX1 P27695 1/20 0.49
THPO P40225 1/20 0.49
PMP22 Q01453 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
TSHR P16473 3/20 0.37
ALDH1A1 P00352 2/20 0.37
MGLL Q99685 2/20 0.34
RAB9A P51151 1/20 0.33
PLA2G1B P04054 1/20 0.33
ATG4B Q9Y4P1 1/20 0.33
P2RX4 Q99571 1/20 0.33
CHRM2 P08172 2/20 0.32
CHRM4 P08173 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1764267 0.85 MEN1 (0.38) KMT2AMEN1LMNACYP3A4CYP2C9
SCHEMBL19172387 0.84 MEN1 (0.37) KMT2AMEN1LMNACYP3A4CYP2C9
SCHEMBL14794931 0.84 MEN1 (0.33) KMT2AMEN1LMNACYP3A4CYP2C9
SCHEMBL2193456 0.83 MEN1 (0.35) KMT2AMEN1LMNACYP3A4CYP2C9
SCHEMBL4699686 0.83 TDP1 (0.35) KMT2AMEN1LMNACYP3A4CYP2C9
SCHEMBL917125 0.83 MEN1 (0.36) KMT2AMEN1LMNACYP3A4CYP2C9
SCHEMBL19543529 0.83 MAPK1 (0.37) KMT2AMEN1LMNACYP3A4CYP2C9
SCHEMBL2147485 0.82 CYP3A4 (0.35) KMT2AMEN1LMNACYP3A4CYP2C9
SCHEMBL13108203 0.82 LMNA (0.35) KMT2AMEN1LMNACYP3A4CYP2C9
SCHEMBL12972246 0.82 KMT2A (0.35) KMT2AMEN1LMNACYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10131681-B2 Aminophosphinic derivatives that can be used in the treatment of pain PHARMALEADS (FR) 2018-11-20 US disclosed
EP-2740736-B1 Aminophosphinic derivatives suitable for use in the treatment of pain PHARMALEADS (FR) 2015-12-09 EP disclosed
EP-2326655-B1 AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN PHARMALEADS (FR) 2014-12-31 EP disclosed
US-20140161839-A1 AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN PHARMALEADS (FR) 2014-06-12 US disclosed
EP-2740736-A1 Aminophosphinic derivatives suitable for use in the treatment of pain Pharmaleads (FR) 2014-06-11 EP disclosed
US-8703747-B2 Aminophosphinic derivatives that can be used in the treatment of pain PHARMALEADS (FR) 2014-04-22 US disclosed
US-8338469-B2 Compounds and compositions as channel activating protease inhibitors IRM LLC (BM) 2012-12-25 US disclosed
US-20110257077-A1 COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS IRM LLC (BM) 2011-10-20 US disclosed
EP-2326655-A1 AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN Pharmaleads (FR) 2011-06-01 EP disclosed
US-7951823-B2 Compounds and compositions as channel activating protease inhibitors IRM LLC (BM) 2011-05-31 US disclosed
WO-2007137080-A2 COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS IRM LLC (BM) 2007-11-29 WO disclosed
US-20070275906-A1 Compounds and Compositions as Channel Activating Protease Inhibitors IRM LLC (BM) 2007-11-29 US disclosed
WO-2006130426-A2 MODULATORS OF CCR-5 ACTIVITY KEMIA, INC. (US) 2006-12-07 WO disclosed
EP-0226217-B1 Peptides with sulfate ester group FISONS CORP (US) 1994-01-26 EP disclosed
US-5086042-A Capable of stimulating contraction of gall bladder; having six to nine amino acids with sulfonated tyrosine and C-terminal amides; treating obesity FISONS CORPORATION (US) 1992-02-04 US disclosed
EP-0417217-A1 PEPTIDES WITH SULPHATE ESTER GROUPS FISONS CORPORATION (US) 1991-03-20 EP disclosed
WO-1990008773-A1 PEPTIDES WITH SULPHATE ESTER GROUPS FISONS CORPORATION (US) 1990-08-09 WO disclosed
EP-0381340-A2 Peptides with sulphate ester groups FISONS CORPORATION (US) 1990-08-08 EP disclosed
EP-0268297-A2 Peptides with sulfate ester groups FISONS CORPORATION (US) 1988-05-25 EP disclosed
EP-0226217-A2 Peptides with sulfate ester group FISONS CORPORATION (a Massachusetts corporation) (US) 1987-06-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257077-A1 COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS PRSS1, PRSS8, PRSS2 KMT2A 4013/4885MEN1 2897/4885LMNA 1370/4885
US-10131681-B2 Aminophosphinic derivatives that can be used in the treatment of pain OPRM1, HRH3, HRH4 KMT2A 3249/4885MEN1 4339/4885LMNA 4614/4885
US-20140161839-A1 AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN OPRM1, HRH3, HRH4 KMT2A 3249/4885MEN1 4339/4885LMNA 4614/4885
US-20070275906-A1 Compounds and Compositions as Channel Activating Protease Inhibitors PRSS1, PRSS8, PRSS2 KMT2A 4013/4885MEN1 2897/4885LMNA 1370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.